Companies Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp.

Seattle

Total Offices: 3

669 Total Employees

Year Founded: 2009

View Website

Adaptive Biotechnologies Corp. Company Growth, Stability & Outlook

Updated on September 09, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Adaptive Biotechnologies Corp. and has not been reviewed or approved by Adaptive Biotechnologies Corp..

What's the stability & growth outlook for Adaptive Biotechnologies Corp.?

Strengths in rapid top-line expansion, improving operating discipline, and supportive analyst sentiment are accompanied by ongoing GAAP losses, milestone-dependent variability, and mounting competitive pressure. Together, these dynamics suggest a growing franchise with improving resilience that must execute in 2026 to translate momentum into durable, company-wide profitability and cash generation.

Key Insight for Candidates

Defining tradeoff: a rapidly scaling, EBITDA-positive MRD franchise versus company-wide GAAP losses and a shrinking Immune Medicine revenue base post‑Genentech. Expect intense focus on clonoSEQ execution, EMR-driven volume growth, and cost discipline as the company prioritizes MRD to achieve sustainable profitability.

Evidence in Action

MRD-First Operating Cadence — 2026 MRD revenue guidance of $255–$265M and the 'MRD engine' contributing 77% of 2025 revenue anchor planning. Employees align goals, sequencing throughput, and field focus to MRD adoption, reinforcing predictable growth and resilience.
Organic Growth Reporting Discipline — Genentech-related amortization of $41.3M in 2025 is excluded to show 42% organic revenue growth. Employees standardize plans and updates on ex‑one‑time metrics, improving forecast accuracy, budget discipline, and recovery speed when external revenue sources shift.

Positive Themes About Adaptive Biotechnologies Corp.

Strong Revenue Growth: Revenue grew significantly year over year with continued quarterly momentum, led by rising clonoSEQ MRD volumes and management guidance for further expansion in 2026.
Cost & Operational Efficiency: Cash burn declined meaningfully and adjusted profitability metrics improved, with the MRD segment achieving positive contribution and initiatives underway to enhance margins and scale.
Investor Backing & Capital Strength: Analyst sentiment is predominantly positive with recent upgrades and targets above current levels, and the company enters 2026 with a solid cash position and a stated goal of positive free cash flow.

Considerations About Adaptive Biotechnologies Corp.

Declining Profitability: Despite improvements, the company remains unprofitable on a GAAP basis and near‑term forecasts still anticipate losses.
Short-Term or Unsustainable Growth: Recent revenue beats included notable one‑time milestone payments and guidance now contemplates reduced milestone contributions, pointing to potential variability in reported results.
Weak Market Position & Pricing Challenges: Competition is intensifying in key blood cancer indications, making the upcoming year a critical test to defend share and sustain MRD momentum.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.